Healthtech TympaHealth secures £2m loan from Innovate UK
This article covers TympaHealth, a healthtech startup that has secured a £2m Innovate UK loan in a debt funding round to accelerate the development and roll-out of Tympa Assist, an AI-guided platform for ear and hearing care in community settings. The funding is intended to expand features such as Otoscopy Assist, build clinical diagnostic functions and integrate referral pathways to support non-specialist practitioners and ease pressure on ENT and audiology services.
TympaHealth, a healthtech startup, has secured a £2 million Innovate UK loan in a debt funding round to accelerate development and roll-out of Tympa Assist, an AI-guided platform aimed at supporting ear and hearing care delivery in community settings. The funding will be used to expand features such as Otoscopy Assist, build clinical diagnostic functions, and integrate referral pathways to ease pressure on specialist services.
Why it matters
Primary and community care are under growing strain to manage routine ear and hearing problems without overburdening ENT and audiology services. Tools that help non-specialist practitioners—pharmacists, care providers and GPs—carry out more consistent assessments and make appropriate referrals could reduce waiting lists and improve access to routine care closer to patients’ homes. A publicly backed loan from Innovate UK signals government interest in shifting parts of care into community settings in line with the NHS Neighbourhood Health Service ambitions.
Inside the product
Tympa Assist combines several components into a single platform rather than offering a single-function device. Its Otoscopy Assist module provides real-time AI feedback on image quality and estimates earwax levels as minimal, moderate, or substantial. The broader platform links high-definition digital otoscopy, hearing screening, microsuction capability and cloud-based referral pathways.
The company says Tympa Assist also offers audiogram assistance and supports referral decision-making while keeping clinical judgement with trained practitioners. TympaHealth is explicit that the system is intended for non-complex presentations and not for individuals with known or suspected complex ENT conditions, consistent with NHS and ENT guidance.
Who are the investors?
The funding comes as a £2 million loan from Innovate UK, delivered through its innovation funding mechanisms. The loan is intended to support product development and scaling of Tympa Assist in community-facing services and to help align the technology with NHS care delivery models rather than to fund early-stage equity growth.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Dr. Krishan Ramdoo, ENT surgeon and founder of TympaHealth, said:
AI is often associated with diagnosis, but that’s not where the biggest challenge lies in everyday ear and hearing care. The real need at the frontline is consistency, confidence, and knowing when to escalate.
In the announcement, Dr. Krishan Ramdoo, ENT surgeon and founder of TympaHealth, said:
Tympa Assist is the first feature to apply AI across the full ear and hearing health workflow, supporting image quality, wax assessment, audiogram assistance and referral decisions, while keeping clinical judgement firmly in the hands of trained practitioners.
The bigger picture
The loan to TympaHealth sits within a wider trend of investment in diagnostic and triage tools intended to move routine care into community settings. For the NHS, the appeal is straightforward: improve access and reduce secondary care demand. For the healthtech sector, demonstrating safe, effective use of AI in frontline workflows is now essential to secure public procurement and wider clinical adoption.
If Tympa Assist proves reliable in real-world community settings, it could become part of a broader shift in how ear and hearing services are delivered across the UK and Europe, though integration with existing referral pathways and clinician oversight will determine its practical impact.
The deal highlights how public funding is being used to de-risk technologies that aim to redistribute routine clinical work across community services, a development likely to influence other UK and European healthtech projects seeking both validation and scale.
They've invested in TympaHealth
Get to know these healthtech investors
Click here for a full list of 7,589+ startup investors in the UK